Health Policy
Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18–44 Years
Breast cancer in women aged 18–44 years accounts for approximately 27,000 newly diagnosed cases and 3,000 deaths annually. When tumors are diagnosed, they are usually aggressive, resulting in expensive treatment costs. The purpose of this study is to estimate the prevalent medical costs attributable to breast cancer treatment among privately insured younger women.Treatment Costs of Breast Cancer Among Younger Women Aged 19–44 Years Enrolled in Medicaid
A few studies have examined the costs of breast cancer treatment in a Medicaid population at the state level. However, no study has estimated medical costs for breast cancer treatment at the national level for women aged 19−44 years enrolled in Medicaid.Healthcare Expenditure Burden Among Non-elderly Cancer Survivors, 2008–2012
There is increasing concern regarding the financial burden of cancer on patients and their families. This study presents nationally representative estimates of annual out-of-pocket (OOP) burden among non-elderly cancer survivors and assesses the association between high OOP burden and access to care and preventive service utilization.Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review
Substantial innovation related to cancer prevention and treatment has occurred in recent decades. However, these innovations have often come at a significant cost. Cost-utility analysis provides a useful framework to assess if the benefits from innovation are worth the additional cost. This systematic review on published cost-utility analyses related to cancer care is from 1988 through 2013. Analyses were conducted in 2013–2015.Health and Economic Impact of Breast Cancer Mortality in Young Women, 1970–2008
Breast cancer is the second-leading cause of cancer-related deaths among women aged <50 years. Studies on the effects of breast cancer mortality among young women are limited.Melanoma Treatment Costs: A Systematic Review of the Literature, 1990–2011
Melanoma is the most deadly form of skin cancer and an important public health concern. Given the substantial health burden associated with melanoma, it is important to examine the economic costs associated with its treatment. The purpose of the current study was to systematically review the literature on the direct medical care costs of melanoma.
